|Bid||9.00 x 800|
|Ask||9.85 x 900|
|Day's Range||8.94 - 9.63|
|52 Week Range||5.60 - 67.20|
|Beta (3Y Monthly)||3.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
CHF Solutions (CHFS) today announced the filing of two new patent applications with the United States Patent and Trademark Office (USPTO) designed to deepen the company’s intellectual property protection for its Aquadex FlexFlow system. One of the two applications is based on the company’s design for a wearable device designed to assist in maintaining peripheral venous blood flow access in the arm during aquapheresis treatment with the Aquadex FlexFlow system. The second application includes multiple potential new features and improvements to the diagnostic capabilities of the Aquadex FlexFlow system, which, if incorporated into the product, would be designed to help ensure optimal patient fluid balance and to dramatically improve usability for healthcare providers.
EDEN PRAIRIE, MN / ACCESSWIRE / November 28, 2018 / CHF Solutions (NASDAQ: CHFS), today announced that it will be presenting at the 11th annual LD Micro Main Event on Wednesday, December 5th at 7:30AM ...
CHF Solutions, Inc. (CHFS) today announced that on November 8, 2018, the independent directors approved four equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to four individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with CHF Solutions, the four individuals, who were not previously employees or directors of CHF Solutions, received options to purchase an aggregate of 15,500 shares of the Company’s common stock.
CHF Solutions, Inc. (CHFS), today announced that it will release an educational webinar featuring the clinical use of the Aquadex FlexFlow system following cardiovascular surgery in patients who have failed diuretic therapy. The webinar will be viewable on the company’s website, https://www.chf-solutions.com/aquapheresis-training-program/ on November 15, 2018 beginning at 12:00 PM ET.
EDEN PRAIRIE, Minn., Nov. 06, 2018 -- CHF Solutions, Inc. (NASDAQ: CHFS) announced today its third quarter results for the period ended September 30, 2018. Highlights include:.
CHF Solutions, Inc. (CHFS) announced today that it has entered into a collaboration agreement with Daxor Corporation (DXR) to explore potential synergies between the company’s Aquadex FlexFlow® System and Daxor’s BVA-100 Blood Volume Analyzer. The company believes that the two technologies can be used together to assess a patient’s fluid volume status and assist in informing on the clinical management of a fluid overloaded patient.
EDEN PRAIRIE, Minn., Oct. 30, 2018 -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its third quarter 2018 financial results will be released on Tuesday, November 6,.
EDEN PRAIRIE, Minn., Oct. 24, 2018 -- CHF Solutions (Nasdaq: CHFS), today announced that Claudia Drayton, chief financial officer, will present and meet one-on-one with.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / CHF Solutions Inc (NASDAQ: CHFS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 9:00:00 AM Eastern Time. ...